Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is an alternative for patients who need a transplant without having conventional donors. One hundred and five consecutive patients with hematologic malignancies who underwent G-CSFprimed peripheral blood haplo-HSCT without in vitro T-cell depletion in our single center were reported in this study. Patients were categorized into the intermediate-risk group (n = 28) or high-risk group (n = 77) according to the risk stratification. The conditioning regimen included fludarabine, busulfan, cyclophosphamide and anti-lymphocyte globulin. The cumulative incidence of grades II-IV acute GvHD (aGvHD) on day +100 was 21.9%, and that of grades III-IV aGvHD was 14.3%. The 2-year cumulative incidence of total chronic GvHD (cGvHD) was 24.1%, and that of extensive cGvHD was 5.6% in 83 eligible patients. The 3-year cumulative incidence rates of relapse and no relapse mortality were 21.9% and 30.5%, respectively. After a median follow-up of 35 months, the 3-year probabilities of overall and disease-free survival for the intermediate-risk and high-risk groups were 63.2% and 39.8% and 61.2% and 32.2%, respectively. In multivariate analysis, the outcome of survival (overall survival and disease-free survival) was associated with the risk stratification, disease status at transplant and dose of infused mononuclear cells. Our results suggest that unmanipulated peripheral blood stem cell allograft performed with fludarabine, busulfan, cyclophosphamide and anti-lymphocyte globulin conditioning regimen is feasible.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the curative therapies for most hematologic malignancies. The best donor for HSCT is a HLA-identical sibling donor. Unfortunately, on the basis of the average family sizes in China, fewer than 30% of patients are able to find a matched sibling donor. 1 For patients without an identical sibling donor, the main alternative choice is an HLA-matched unrelated donor through the registries of volunteer donors; 2 however, only one-third of them are able to find fully HLA-matched donors. Almost all patients have at least one available donor from their families, and HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is a feasible therapy for those without an identical related or unrelated donor. 3, 4 However, the high rates of severe GvHD, engraftment failure and infection have remained the major obstacles for successful haplo-HSCT. 5 Different haploidentical 'transplant platforms' have been established by either intensive myeloablative conditioning or reduced intensity conditioning using either T-cell-depleted (TCD) or TCR grafts. [6] [7] [8] Because of the high incidence rates of no-relapse mortality (NRM) and severe infection, a 'mega-dose' HSCT protocol, involving CD34 + selection in vitro to deplete T-cells without any post-transplant immune suppression, reported by Aversa et al. 5 has rarely been performed in China. Bethge et al. 9 developed a TCD transplant platform consisting of negative selection of lymphocyte subsets through CD3/CD19 or TCRαβ and reservation of other donor immune cells, such as natural killer cells, to decrease the rates of infection and relapse. However, the outcomes of this TCD protocol were not superior to those of the 'mega-dose' of CD34 + cells approach. One TCR transplantation protocol was established by Huang et al., 10 known as the 'GIAC' protocol for haplo-HSCT, with unmanipulated bone and blood grafts and immunosuppression for GvHD prophylaxis. Luznik et al. 6 developed another TCR transplant platform using posttransplant cyclophosphamide (PT/Cy) with a nonmyeloablative regimen to promote haplo-HSCT with a fast recovery of T-cell subpopulations and low rates of GvHD and NRM. Although the two TCR haplo-HSCT protocols reported by Huang et al. and Luznik et al. achieved good engraftment and survival with acceptable incidence rates of NRM and GvHD in a single institution, it is still a relatively complex procedure to harvest stem cells from both the peripheral blood and the bone marrow according to Huang et al.'s 'GIAC' protocol, 10 and the incidence of relapse was high in Luznik et al.'s 6 study with the use of a nonmyeloablative regimen.
In our institution, we established a conditioning regimen consisting of fludarabine, busulfan, cyclophosphamide and antilymphocyte globulin (FBCA) with the use of G-CSF-primed peripheral blood for haplo-HSCT without in vitro T-cell depletion. In the present study, we analyzed 105 consecutive patients who underwent transplant with this protocol from 2000 to 2013 to investigate the feasibility of this approach in treating hematologic malignancies.
MATERIALS AND METHODS

Study setting and data collection
This study was a retrospective single-center analysis. Between 1 September 2000 and 31 December 2013, 105 consecutive patients with hematologic malignancies underwent haplo-HSCT at the department of hematology of Zhujiang Hospital of Southern Medical University of China. We enrolled patients with hematopoietic malignancies who needed haplo-HSCT without available HLA-identical related or unrelated donors or a source of stem cells from cord blood. Patients with severe infections or major organ (that is renal, liver, lung or heart) disease were not eligible for haplo-HSCT. Patients with a low risk in accordance with the risk stratification 11 were not treated with haplo-HSCT at our center. This study was approved by the board of ethics of Zhujiang Hospital. Informed consent was obtained from all patients and donors before the initiation of the protocol.
HLA disparity, stem cell harvest and conditioning regimen HLA type I and II antigens were detected with high-resolution DNA typing. Donors were administered G-CSF at a total daily dose of 10 μg/kg subcutaneously in two split doses on days − 4 and 0. Peripheral blood mononuclear cells were harvested on day 0 and infused through a central venous catheter on the same day.
All patients received an FBCA conditioning regimen, which consisted of fludarabine (25 mg/m 2 /day, intravenous) on days − 9 to − 5, busulfan (3.2 mg/kg/day, intravenous) on days − 8 to − 5, cyclophosphamide (60 mg/kg/day, intravenous) on days − 3 to − 2 and rabbit antilymphocyte globulin (ATG, anti-lymphocyte globulin, Sanofi Company, 2.5 mg/kg/day, intravenous) on days − 5 to − 1.
GvHD prophylaxis and supportive care
All patients were given a combination of cyclosporine A (CsA) and shortterm methotrexate for GvHD prophylaxis. CsA was administered (3 mg/kg/ day) by continuous intravenous infusion on day − 1 and switched to oral CsA as soon as patients were off intravenous therapy. The CsA should be tapered gradually and stopped after 180-270 days without GvHD. All patients received methotrexate (15 mg/m 2 /day, day +1; 10 mg/m 2 /day, days +3, +6 and +11) after transplantation. If patients were diagnosed with acute GvHD (aGvHD), methylprednisolone was intravenously administered at a dose of 2 mg/kg/day. Second-line immunosuppressive therapy, such as a CD25 monoclonal antibody, was given for steroidrefractory aGvHD.
Patients were nursed with single-patient, HEPA filters. They were given leukocyte-filtered blood products to maintain hemoglobin levels above 60 g/L and platelet counts above 20 × 10 9 /L. Acyclovir was given as herpes prophylaxis from days − 10 to +90, and trimethoprim-sulfamethoxazole was given from days − 10 to +180 in order to prevent Pneumocystis carinii infection. Before 2008, itraconazole was given for fungal prophylaxis; after 2008, voriconazole was given instead of itraconazole for preventing fungal infection from days − 10 to +90. All patients accepted ganciclovir (5 mg/kg/ day) from days − 14 to − 2 for CMV infection prophylaxis. The G-CSF and recombinant human TPO were subcutaneously injected on day +1 until the hematopoietic reconstitution.
Follow-up
Routine blood testing was performed once a week within the first three months following the haplo-HSCT. The whole-blood CsA concentration was monitored weekly, and the dosages were adjusted to maintain CsA concentrations of 100-200 ng/ml. CMV and EBV DNA copies were detected weekly using real-time PCR during the first three months. A bone marrow smear and chimerism were checked once a month by DNA fingerprinting of a short tandem repeat with PCR or sex chromosomal FISH. The CD4 + and CD8 + cell counts in the peripheral blood were calculated by flow cytometry at 1, 3, 6 and 12 months after haplo-HSCT. The quality of life of survivors was evaluated using the Karnofsky Performance Status after haplo-HSCT.
Definition
The endpoint of this retrospective study was 31 December 2013. The primary outcomes analyzed were the following: overall survival (OS), disease-free survival (DFS, malignancies relapsed at any time of the followup or death after transplant), relapse of malignancy, NRM, aGvHD and chronic GvHD (cGvHD). Neutrophil engraftment was defined as a blood ANC exceeding 0.5 × 10 9 /L for consecutive 3 days after transplantation. Platelet engraftment was defined as a platelet count exceeding 20 × 10 9 /L for 7 continuous days without transfusion.
The patients diagnosed as having hematologic malignancies in our center were categorized as 'low-risk,' 'intermediate-risk' and 'high-risk' according to the published risk stratification.
11 AML and myelodysplastic syndrome cytogenetics were classified according to established criteria. 12 The patients categorized as low-risk were not eligible for haplo-HSCT in our center. A total of 105 patients who were classified as intermediate-or highrisk were enrolled in our cohort. For AML, patients with intermediate cytogenetics who failed induction therapy or had relapse at transplant were categorized as high-risk, and patients with adverse cytogenetics, regardless of their disease status at transplant, were also categorized as high-risk. Patients with ALL who failed induction therapy, had active relapse at transplant or had t (9, 22) , t(4,11), and complex were classified as high-risk. For CML, patients in the accelerated or blast-phase were categorized as intermediate-risk. For myelodysplastic syndrome, patients who scored 42.5 according to the International Prognostic Scoring System were considered high-risk. Patients who were ineligible for high-risk criteria were classified as intermediate-risk. The diagnosis and grading of GvHD was in accordance with published criteria.
14 The cumulative incidence of aGvHD was assessed within 100 days after transplant, and the incidence of cGvHD was evaluated in patients surviving more than 100 days after transplant with allogeneic engraftment. Relapse was described as any recurrence of signs or symptoms of primary hematologic diseases after transplantation. Flow cytometry and molecular data were not used to define relapse.
Statistics
Distributions for the OS and DFS were calculated with the Kaplan-Meier method. The Kaplan-Meier curves were compared using the log-rank test. The cumulative incidence rates of aGvHD, cGvHD, NRM and relapse were computed using cumulative incidence curves. The Gray method 15 was used for comparisons of the cumulative incidence curves with competing risks. The Cox proportional hazard regression model was used in multivariate analyses with variables containing the age, disease status at transplantation, risk stratification, HLA disparity and dose of infused mononuclear cells. A forward stepwise model selection approach was used to identify the significant variables listed above. All P-values were twosided, and a P-value o0.05 was used as the cut-off for statistical significance. A statistical software package (SPSS 17.0, SPSS Inc. 1993-2007 and R Software, Boston, MA, USA) was used for all analyses.
RESULTS
Patients characteristics
The characteristics of the patients studied are summarized in Table 1 . There were 68 males and 37 females with a median age of 23 (range, 9-57) years at the time of haplo-HSCT. Patients were diagnosed with ALL (n = 43), AML (n = 32), CML (n = 18) and myelodysplastic syndrome (n = 12). The median time of follow-up was 35 months (range, 6-155 months). Twenty-eight patients were categorized as intermediate-risk, while 77 patients were high-risk. Forty-three patients achieved a first CR (41.0%) and 18 a second CR (17.1%); the remainder (41.9%) did not achieve remission at transplant. Sixteen patients were matched for 8 of 10 HLA-A, -B, -C, -DRB1 and -DQB1 allele loci (8/10); 59 patients were matched for 6 of 10 allele loci (6/10); and 30 patients were for 5 of 10 allele loci (5/10).
Engraftment
The median cell doses of mononuclear cells and CD34 + cells in the graft were 6.68 (1.10-17.23) × 10 6 /kg and 8.20 (1.50-16.70) × 10 8 / kg, respectively. One hundred two patients (102/105) achieved myeloid, platelet reconstitution and steady full-donor chimerism after transplantation. Two patients died of severe infection before hematopoietic reconstitution. One patient had later graft failure on day 206 after transplant, received a second haplo-HSCT from the origin donor, and then achieved complete hematopoietic recovery. The median time for neutrophil engraftment was 14 days (range, 10-25 days); for platelet recovery, it was 16 days (range, 9-38 days).
GvHD
Of the 105 patients, the cumulative incidence of grades II-IV aGvHD on day +100 was 21.9% ± 7.8%, and that of grades III-IV aGvHD was 14.3% ± 6.7%. aGvHD occurred in 7 of 16 (43.8%) patients who matched for 8/10 loci, 36 of 59 (61.0%) patients with 6/10 loci and 20 of 30 (66.7%) patients with 5/10 loci. Moreover, the incidence of grades III-IV aGvHD was lower in patients who matched for 8/10 loci compared with those matched for 5/10 loci (0% versus 34.3%, P = 0.053) (Figure 1) . Eighty-three patients who survived longer than 100 days after transplant were eligible to be evaluated for the incidence of cGvHD. Twenty-two patients developed cGvHD; four of them showed extensive cGvHD. The 2-year cumulative incidence of cGvHD was 24.1% ± 9.4%, and that of extensive cGvHD was 5.6% ± 5.3% (Figure 2 ). cGvHD was diagnosed in 4 of 16 (25.0%) patients with 8/10 loci matched, 13 of 59 (22.0%) patients with 6/10 loci matched and 5 of 30 (16.7%) patients with 5/10 loci.
Overall and disease-free survival The estimated 3-year probabilities of OS and DFS were 50.6% ± 10.8% and 41.1% ± 11.8%, respectively. The 3-year probabilities of OS and DFS for the intermediate-risk group were 63.2% ± 13.4% and 61.2% ± 9.4%; for the high-risk group, they were 39.8% ± 12.5% and 32.2% ± 12.7%, respectively (Figure 3) . A higher dose of infused mononuclear cells (hazard ratio (HR) = 0.846; confidence interval (CI): 0.765-0.935; P = 0.000) was a good prognostic factor for DFS, while patients in the high-frisk group (HR = 5.058; CI: 2.149-11.906, P = 0.001) tend to have a lower incidence of DFS. A similar result was observed for the OS (Table 2 ). No significant difference in the survival was noted according to the number of HLA loci matched.
Relapse and no-relapse mortality The 3-year cumulative incidence of relapse was 21.9% ± 7.8%. At the study end point, 23 patients had experienced relapse after Abbreviations: HSCT = hematopoietic stem cell transplant; MDS = myelodysplastic syndrome; MNC = mononuclear cell; NR = no remission. transplant, including 3 patients in the intermediate-risk group and 20 patients in the high-risk group. The 3-year cumulative incidence rates of relapse in the intermediate-and high-risk groups were 10.7% ± 11.1% and 26.0% ± 9.6%, respectively (P = 0.093) (Figure 4 ). The multivariate analyses showed that the disease status of no remission at transplant (HR = 3.302; CI:
1.123-9.711, P = 0.03) was a significant risk factor for relapse ( Table 2 ). The total 3-year cumulative incidence of NRM was 30.5 ± 10.2%, while the 100-day cumulative incidence of NRM was 15.8% ± 7.1%. In the intermediate-and high-risk groups, the cumulative incidence rates of NRM were 8.6% ± 11.4% and 44.2% ± 12.9% (P = 0.003), respectively. Twenty patients underwent haplo-HSCT between 2000 and 2007, and the 3-year cumulative incidence of NRM among these patients was 50.0% ± 14.4%. The 3-year NRM, including 85 patients who underwent haplo-HSCT between 2008 and 2013, was 25.9% ± 9.2%. A total of 48 patients died, and the major cause of death was infection (39.6%), followed by relapse (31.25%) and severe aGvHD (14.6%), organ failure in three patients, hemorrhage in three patients and epilepsy in one patient ( Table 3) . The CMV and EBV viremia levels detected by PCR were 49.5% and 51.2% after transplant, whereas no posttransplant lymphoproliferative disease was observed in this patient population.
Immune reconstitution and quality of life The immune reconstitution was slow. Although the CD8 + cell count in the peripheral blood returned to a normal level within 3 months after haplo-HSCT (median count: 652.40/μL; range: 365.00-2481.60/μL), the CD4 + cell count was low until 1 year post haplo-HSCT. The median cell counts of CD4 + cells in the Abbreviations: DFS = disease-free survival; HSCT = hematopoietic stem cell transplant; MNC = mononuclear cell; NR = no remission; OS = overall survival.
peripheral blood at 3, 6 and 12 months after haplo-HSCT were 152.95/μL (range: 16.50-312.00), 287.46/μL (66.00-783.13) and 386.00/μL (120.90-1161.60), respectively. On 31 December 2013, 57 patients were still alive, and 52 patients achieved DFS through the follow-up. The Karnofsky Performance Status (KPS) score was more than 90 in the patients with DFS.
DISCUSSION
Haplo-HSCT is an alternative for patients with refractory hematological malignancies who urgently need transplants without related or unrelated HLA-matched donors. There are several advantages of haplo-HSCT, including immediate access to a donor and a stronger graft-versus-tumor effect because of HLA disparity. 16 Nevertheless, the problems of engraftment failure and lethal GvHD remain. In 1998, Slavin et al. 17 introduced a relatively non-myeloablative regimen with G-CSF-primed peripheral blood. This transplant protocol achieved a low incidence of transplant-related mortality and GvHD with a good graft-versus-leukemia effect. Inspired by this protocol, we 18 established a nonmyeloablative regimen, including fludarabine, busulfan and cyclophosphamide with only G-CSF-primed peripheral blood without in vitro TCD in 1998. Between 1998 and 2000, we observed a low incidence of aGvHD with good survival among patients who underwent haplo-HSCT with our conditioning regimen. However, the patients suffered from high incidences of relapse and cGvHD (data not published). Therefore, we modified the original regimen by increasing the drug dosages of fludarabine and cyclophosphamide, changing the usage of busulfan from oral to intravenous and adding ATG in 2000. Since then, we began to use this myeloablative regimen, named FBCA, with G-CSF-primed peripheral blood without in vitro TCD for haplo-HSCT.
In this retrospective analysis of haplo-HSCT based on the FBCA conditioning regimen, our results with this approach show favorable long-term survival and DFS. The estimated 3-year probabilities of OS and DFS were 50.6% and 41.1%, respectively. With our protocol, the respective 3-year probabilities of OS and DFS for the intermediate-risk group were 63.2% and 61.2%; for the high-risk group, they were 39.8% and 32.2%. Using the GIAC approach, 8 Huang et al. reported on 756 patients with hematologic malignancies (195 high-risk) who underwent unmanipulated HLA-mismatched blood and bone marrow transplantation; the 3-year probabilities of OS and DFS were 67% and 63%, respectively. With the use of the PT/Cy transplant protocol, Bacigalupo et al. 19 reported on 50 patients (27 at high-risk) with hematologic malignancies who underwent haplo-HSCT; the 22-month respective probabilities of the DFS for standard-and high-risk patients were 68% and 37%, respectively. Although these results could not be directly compared due to the different risk stratifications and patient populations, our data were not inferior to these two TCR transplant protocols.
Without in vitro TCD, a higher incidence of GvHD was observed in the TCR transplant protocol in early research. However, some approaches of GvHD prophylaxis have been developed to solve this problem. GvHD prophylaxis includes the administration of PT/Cy, ATG and various monoclonal antibodies. In our study, ATG was administered as part of the conditioning regimen. The administration of ATG before transplantation can induce apoptosis of various lymphocytes, strongly suppressing the immune function, 20 and can significantly reduce the incidence rates of aGvHD and cGvHD. 21 A low dose of rabbit-ATG (2.5 mg/kg/day for 4 days) was used in Huang's GIAC protocol. 8 He reported incidence rates of acute grades II-IV, grades III-IV and cGvHD of 43%, 14% and 53%, respectively. Different from Huang's study, we used a median dose of ATG of 2.5 mg/kg/day for 5 days. The cumulative incidence of grades III-IV aGvHD (14% vs 14.3%) was similar, while the cumulative incidence rates of grades II-IV aGvHD (43% vs 21.9%) and cGvHD (53% vs 24.1%) were relatively lower in our study compared with Huang's study. Compared with Bacigalupo's haplo-HSCT protocol with a PT/Cy approach, 19 the cumulative incidence of aGvHD was higher in our cohort, and the incidence rates of cGvHD were comparable in both protocols. Although high dose of ATG was used in the current study, it did not significantly delay immune recovery compared with those reported by The Peking University Group and The Baltimore Group. 22 Our analysis suggested that the 3-year cumulative incidence of NRM was 30.5%. The NRM in our study was higher than in those of Haplo-HSCT a feasible therapy for those without an identical donor X Lin et al
Huang's GIAC protocol 8 (18%) and Bacigalupo's PT/Cy transplant method (18%). 19 However, there are some reasons for the higher NRM in our group. Because of the poor efficacy of itraconazole for fungal prophylaxis before 2008, we observed that the 3-year incidence of NRM between 2000 and 2007 was as high as 50%. Since then, we have used voriconazole instead of itraconazole for the prevention of fungal infection and have found that the 3-year incidence of NRM between 2008 and 2013 decreased to 25.9%. Although the comparison between these two time periods did not reach statistical significance, there was a declining trend of NRM. As more patients in our group were at a disease status or had relapsed more than twice at transplant and were at high risk of developing clinical complications, the cumulative incidence of NRM was significantly higher in the high-risk group than in the intermediate-risk group (44.2% vs 8.6%, P = 0.003) in our cohort.
The total incidence of relapse was 21.9% in our patient cohort. The 3-year probabilities of relapse in the intermediate-and highrisk groups were 10.7% and 26.0%, respectively, similar to Huang's study 8 and Bacigalupo's PT/Cy protocol. 19 Although the incidence of CMV infection was still high (49.5%), we frequently monitored the copies of CMV DNA and preemptively treated patients when there were 410 3 CMV DNA copies after transplant, and no CMV-related disease was observed in this cohort.
In summary, the FBCA conditioning regimen using peripheral blood stem cell allograft allows successful unmanipulated haplo-HSCT for hematologic malignancy patients who lack a suitable donor. A prospective multicenter study is needed to confirm this approach.
